Clinical trials
catalyst calendar across sponsors →Studies where RANI is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional · 1 with posted results
Held by 7 tracked-famous managers (CITADEL ADVISORS LLC, MARSHALL WACE, LLP, JANE STREET GROUP, LLC, RENAISSANCE TECHNOLOGIES LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, +2 more) · FINRA short interest 6.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.NCT06891287To evaluate safety and tolerability of RT-114 by assessing treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Combination product: RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity · Drug: PG-102 · Other: Placebo | Obesity | 60 | 2026-12-01 | in 104 d | 2026-04-14 |
| Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ CapsuleNCT05890118Evaluate Cmax of ustekinumab administered via the RaniPill capsuleNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Stelara · Combination product: RT-111 (0.5mg), RT-111 (0.75mg) | Healthy Volunteers | 55 | 2023-11-28actual | — | 2024-01-11 |
| Study Evaluating PK of PTH Administered Orally Via RaniPill™ CapsuleNCT05164614Evaluate Cmax of PTH administered via the RaniPill capsuleNon-randomized · Open-label · Treatment | Phase 1 | Completed | Combination product: RT-102 (80 μg), RT-102 (20 μg) · Drug: Forteo | Healthy Volunteers | 50 | 2022-10-10actual | — | 2022-10-31 |
| Pill Swallow StudyNCT04911296results2025-02-12Successful Swallowing of the Mock-RPOpen-label · OtherStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Other: Mock-RP | Not Determined | 150 | 2021-08-27actual | — | 2025-02-12 |
| A First-in-Human Study of the RaniPill, an Oral Drug Delivery PlatformNCT03798912Incidence and kind of adverse events possibly related to the RaniPill capsuleNon-randomized · Open-label · Treatment | Phase 1 | Completed | Combination product: RaniPill capsule containing octreotide | Healthy Volunteers | 62 | 2020-02-17actual | — | 2020-10-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19